The Joint's third-quarter revenue rose 1% year over year to $13.6 million, missing the $14.85 million analyst estimate. The company lowered its 2026 system-wide sales outlook to $508 million-$512 million, while maintaining adjusted EBITDA guidance of $12.5 million-$13.5 million.
The Joint reported third-quarter revenue of $13.6 million, up 1% year over year and below the $14.85 million consensus estimate. Net income from continuing operations increased to $1.5 million from $290,000 a year earlier, while loss per share was $0.01.
The company now expects 2026 system-wide sales of $508 million to $512 million, down from its prior range of $519 million to $552 million. It maintained 2026 consolidated adjusted EBITDA guidance of $12.5 million to $13.5 million. Higher active membership and lifetime value per member were partly offset by lower average patient spending and fewer new patients; the company cited macroeconomic challenges.
The Joint repurchased $3.8 million of stock and authorized an additional $5 million buyback. Lower regional developer royalty costs following the reacquisition of territories reduced cost of revenues, while general and administrative expenses fell with cost controls and a leaner structure after refranchising.
